Journal of Personalized Medicine (JPM)
Publisher: MDPI AG
Journal of Personalized Medicine (JPM) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform.
JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts.
For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects.
We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
Topics of interest with a view towards personalized medicine include (but are not limited to) the following:
* ‘omics technologies (genomics, transcriptomics, proteomics, epigenomics, metabolomics, lipidomics, interferomics).
* next-generation sequencing developments and genome-wide association studies
* biomarker research, development and application
* drug target discovery and development
* personalized health informatics (data mining, diagnosis, analysis)
* regulatory environments
* legal and social consequences of personalized medicine
* personalization of health interventions for improved safety, efficacy and sustainability. (e.g., drug therapy, nutrition) and variability in environment
* biochip/microarray technologies
* genetic testing, disease screening and molecular diagnostics for risk factors, preventative treatment and targeted therapy, and integration with therapy
* genetics and the biochemistry and physiology of drug action, uptake and metabolism; information for drug selection and dosage
* genetics based vaccine development
* genetics-based clinical trials methodology
* prediction-based drug safety; understanding adverse drug reactions
* bioinformatics (databases, data mining, modeling and simulation, signal/image analysis)
Manuscript submission via online system.
Prof. Dr. Urs A. Meyer
University of Basel
CH-4056 Basel, Switzerland
Tel. +41 61 267 2220; Fax: +41 61 43 535 9049
Abstracts available online. Articles available in PDF format.
Current Issue: Volume 1, Issue 1 (December 2011)
Date: 15 February 2012